Physician profile
John C Vanstone
NPI 1083648935
$27,751.50
in general payments reported to CMS, 2019-2025
14 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,022 · 2020: $4,892 · 2021: $5,336 · 2022: $4,160 · 2023: $3,606 · 2024: $4,623 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $7,934 · Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $7,934.15 |
| Food and Beverage | $407.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17,430.34 | 2021-2024 | Palindrome, Mahurkar |
| Covidien Lp | $9,570.44 | 2019-2020 | |
| Amgen INC. | $249.98 | 2019-2025 | Parsabiv, Epogen, Aranesp |
| Otsuka America Pharmaceutical, INC. | $67.74 | 2019-2024 | Jynarque |
| Travere Therapeutics, INC. | $64.76 | 2020-2025 | |
| Horizon Therapeutics Plc | $59.52 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $57.65 | 2019 | |
| Akebia Therapeutics INC | $55.94 | 2019 | |
| Mallinckrodt Hospital Products INC. | $48.31 | 2024-2025 | Terlivaz |
| Genzyme Corporation | $44.56 | 2019-2020 | |
| Chiesi USA, INC. | $31.19 | 2023 | Elfabrio |
| Vifor Pharma, INC. | $29.56 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.24 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $20.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vanstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.